

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition characterised in that it contains at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition and comprises a mono or multiphase sequence of pharmaceutical dosages.
2. (Original) A pharmaceutical preparation according to claim 1 characterised in that it comprises pharmaceutical dosages for the administration over a total time of 56, 84, 112, 140, or 168 days.
3. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~and 2~~ characterised in that the second composition comprises a one phase sequence of pharmaceutical dosages.
4. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~and 2~~ characterised in that the second composition comprises a two phase sequence of pharmaceutical dosages.
5. (Original) A pharmaceutical preparation according to claim 3 characterised in that the pharmaceutical dosage of at least one estrogen of the second composition is higher than the amount contained in the first composition.

6. (Original) A pharmaceutical preparation according to claim 3 characterised in that the pharmaceutical dosage of at least one progestin of the second composition is higher than the amount contained in the first composition.
7. (Original) A pharmaceutical preparation according to claim 4 characterised in that the pharmaceutical dosage of at least one estrogen and/or at least one progestin of the second composition are higher than the amount contained in the first composition.
8. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~anyone of the previous claims~~ characterised in that the at least one estrogen is selected from the group consisting of following synthetic estrogens: ethinylestradiol, mestranol, quinestrinol, or a precursors capable of liberating such an synthetic estrogen and/or from the group of the following biogenic estrogens: estradiol, estrone, estran, estriol, estetrol, conjugated equine estrogens, precursors capable of liberating such a biogenic estrogen.
9. (Original) A pharmaceutical preparation according to claim 8 characterised in that the at least one estrogen is ethinylestradiol and/or estradiol.
10. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~anyone of the previous claims~~ characterised in that the daily hormone units of estrogen preferably contain ethinylestradiol in an amount of 0.005-50 mg, most preferably in an amount of 0.0050.030 mg and/or the estradiol in an amount of to 0.1-5.0 mg.

11. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~anyone of the previous claims~~ characterised in that the at least one progestin is selected from the group consisting of levonorgestrel, norgestimate, norethisterone, dydrogesterone, drospirenone, 3-betahydroxydesogestrel, 3-keto desogestrel (=etonogestrel), 17-deacetyl norgestimate, 19norprogesterone, acetoxypregnenolone, allylestrenol, anagestone, chlormadinone acetate, cyproterone acetate, demegestone, desogestrel, dienogest, dihydrogesterone, dimethisterone, ethisterone, ethynodiol diacetate, flurogestone acetate, gastrinon, gesiodene, gestrinone, hydroxymethylprogesterone, hydroxyprogesterone, lynestrenol (=lynoestrenol), medrogestone, medroxyprogesterone acetate, megestrol, melengestrol, nomegestrol, norethindrone (=norethisterone), norethynodrel, norgestrel (includes d-norgestrel and dl norgestrel), norgestrienone, nonnethisterone, progesterone, quingestanol, (17 alpha)- 17-hydroxy-11-methylene- 19-norpregna-4,15diene-20-yn-3-one, tibolone, algestone acetophenide, nestorone, promegestone, 17 hydroxyprogesterone esters, 19-nor-17hydroxyprogesterone, 17alpha-ethinyl estosterone, 17alpha-ethinyl- 19-nor-testosterone, d- 17beta-acetoxy- 13 beta-ethyl17alpha-ethinyl-gon-4-en-3-one oxime. hydroxytriendione ((21 S)-21-hydroxy-21methyl-14,17ethano-19-nor-pregna-4,9,15-triene-3,20-dione), 5- {2-hydroxy-3 -[1-(2fluoro-5-trifluoromethylphenyl)-cyclopropyl]-2-trifluoromethyl-propionylamino) - phthalide and precursors thereof.
12. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~anyone of the previous claims~~ characterised in that the at least one progestin is preferably selected from the group consisting of levonorgestrel, dienogest, gestodene, drospirenone, and precursors thereof.
13. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~anyone of the previous claims~~ characterised in that the daily hormone units of at least a progestin for use during the whole extended treatment preferably contain the progestin in an amount of

0.05-0.25 mg of levonorgestrel and/or 0.5-5 mg of dienogest and/or 0.03-0.15 mg of gestodene, and/or 0.5-5 mg of drospirenone or equivalent dosages of other progestins.

14. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~anyone of the previous claims~~ characterised in that the hormone units are administered orally, parenterally, sublingually, transdermally, intravaginally, intranasally or buccally.
15. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~anyone of the previous claims~~ characterised in that the hormone units are for oral administration.
16. (Currently Amended) A pharmaceutical preparation according to claim 1 ~~anyone of the previous claims~~ characterised in that the hormone units are daily units.
17. (Currently Amended) Use of a pharmaceutical preparation according to claim 1 ~~claims 1 to 16~~ for the manufacture of an agent for inhibiting ovulation in a mammal, in particular a human.
18. (Original) Use of a pharmaceutical preparation according to claim 17 characterised in that the administration of said preparation extends over a time of 56, 84, 112, 140 or 168 days.
19. (Currently Amended) Use of a pharmaceutical preparation according to claim ~~17 to 18~~ for the manufacture of an agent for diminishing symptoms related to hormonal withdrawal such as premenstrual symptoms, dysmenorrhea, endometriosis, menstrual migraine.
20. (Currently Amended) Use of a pharmaceutical preparation according to claim ~~17 to 18~~ for the manufacture of an agent for diminishing symptoms related to acne

21. (Original) A pharmaceutical package for an extended regimen treatment longer than 21-28 days comprising:
- a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days
 - a second composition containing at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition to be administered in the following of the treatment and comprising a mono or multiphase sequence of pharmaceutical dosages.
22. (Currently Amended) Pharmaceutical package according to claim 1 ~~claim 21~~ characterised in that said first composition and said second compositions are contained in the package ~~correspond to the first and the second composition as defined in the pharmaceutical preparation according to claim 1 to 16.~~
23. (Currently Amended) Pharmaceutical package according to claim 21 ~~and 22~~ characterised in that the first and/or the second composition are administered in daily doses.
24. (Currently Amended) Pharmaceutical package according to claim 21 ~~anyone of the claims 21 to 23~~ characterised in that the first and/or the second composition are arranged for separate sequential administration like for example in separate blisters.
25. (Currently Amended) Pharmaceutical package according to claim 21 ~~anyone of the claims 21 to 24~~ characterised in that the administration of the first and second composition extends over a time of 56, 84, 112, 140 or 168 days.